This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2002;287:2203.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has issued a guidance to assist sponsors who will be submitting information to the Clinical Trials Data Bank established under the Food and Drug Administration Modernization Act of 1997 (FDAMA). The data bank is intended to be a central comprehensive resource, providing current information on certain clinical trials to patients, other members of the public, and health care providers and researchers.

The FDAMA requires that sponsors of all federally and privately funded clinical trials for experimental drugs and biological products that are conducted under an investigational new drug (IND) application post data to the databank, provided that the studies are for treatment of a serious or life-threatening disease or condition and that trials are designed to test effectiveness. If they wish, sponsors can also provide information on other trials conducted under an IND application.

Sponsors are required to submit a description of the purpose of the experimental drug, . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?